Applied Therapeutics is a biotechnology business based in the US. Applied Therapeutics shares (APLT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.57 – an increase of 4.89% over the previous week. Applied Therapeutics employs 37 staff and has a market cap (total outstanding shares value) of 0.00.
Offer ends 4/1/25. Customer must fund their Active invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $2,000 is 0.028%. See full terms and conditions at https://www.sofi.com/greenintwoterms/.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – APLT.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Applied Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Applied Therapeutics stock price (NASDAQ: APLT)
Use our graph to track the performance of APLT stocks over time.
Is it a good time to buy Applied Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Applied Therapeutics price performance over time
Historical closes compared with the close of $0.5731 from 2025-03-21
1 week (2025-03-14)
11.63%
1 month (2025-02-24)
5.50%
3 months (2024-12-24)
-32.70%
6 months (2024-09-24)
-92.93%
1 year (2024-03-22)
-91.51%
2 years (2023-03-23)
-31.77%
3 years (2022-03-23)
2.02
5 years (2020-03-23)
27.99
Applied Therapeutics financials
Gross profit TTM
$-52,564,000
Return on assets TTM
-76.01%
Return on equity TTM
-473.39%
Profit margin
0%
Book value
$0.05
Market Capitalization
$63.6 million
TTM: trailing 12 months
Applied Therapeutics share dividends
We're not expecting Applied Therapeutics to pay a dividend over the next 12 months.
Applied Therapeutics share price volatility
Over the last 12 months, Applied Therapeutics's shares have ranged in value from as little as $0.4331 up to $10.6237. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Applied Therapeutics's is 1.884. This would suggest that Applied Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Applied Therapeutics overview
Applied Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Frequently asked questions
null What percentage of Applied Therapeutics is owned by insiders or institutions? Currently 5.682% of Applied Therapeutics shares are held by insiders and 107.365% by institutions.How many people work for Applied Therapeutics? Latest data suggests 37 work at Applied Therapeutics.When does the fiscal year end for Applied Therapeutics? Applied Therapeutics's fiscal year ends in December.Where is Applied Therapeutics based? Applied Therapeutics's address is: 545 Fifth Avenue, New York, NY, United States, 10017What is Applied Therapeutics's ISIN number? Applied Therapeutics's international securities identification number is: US03828A1016What is Applied Therapeutics's CUSIP number? Applied Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03828A101
A deep dive into the highlights and limitations of Robinhood.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
